Drugs /
regn5678
Back to Drugs List
Overview
NCI Definition [1]:
A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of anti-PSMA/CD28 bispecific antibody REGN5678, this bispecific antibody binds to both CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.
Clinical Trials
Regn5678 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating regn5678, 1 is phase 1/phase 2 (1 open).
Prostate adenocarcinoma is the most common disease being investigated in regn5678 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
